VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Cytogenetic risk stratification in FLT3-mt NPM1-negative AML undergoing alloSCT in remission

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the role of cytogenetic risk stratification in FLT3-mutated NPM1-negative patients with AML undergoing allogeneic stem cell transplantation (alloSCT) in remission. In these patients, cytogenetic risk is significantly associated with outcome and therefore an important prognosticator in FLT3-mutated, NPM1-negative AML patients undergoing alloSCT. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter